253 related articles for article (PubMed ID: 30720226)
1. Neuroplastin-β mediates S100A8/A9-induced lung cancer disseminative progression.
Sumardika IW; Chen Y; Tomonobu N; Kinoshita R; Ruma IMW; Sato H; Kondo E; Inoue Y; Yamauchi A; Murata H; Yamamoto KI; Tomida S; Shien K; Yamamoto H; Soh J; Futami J; Putranto EW; Hibino T; Nishibori M; Toyooka S; Sakaguchi M
Mol Carcinog; 2019 Jun; 58(6):980-995. PubMed ID: 30720226
[TBL] [Abstract][Full Text] [Related]
2. Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
Chen Y; Sumardika IW; Tomonobu N; Winarsa Ruma IM; Kinoshita R; Kondo E; Inoue Y; Sato H; Yamauchi A; Murata H; Yamamoto KI; Tomida S; Shien K; Yamamoto H; Soh J; Liu M; Futami J; Sasai K; Katayama H; Kubo M; Putranto EW; Hibino T; Sun B; Nishibori M; Toyooka S; Sakaguchi M
Cancer Lett; 2019 Jun; 452():178-190. PubMed ID: 30904617
[TBL] [Abstract][Full Text] [Related]
3. Neuroplastinβ-mediated upregulation of solute carrier family 22 member 18 antisense (SLC22A18AS) plays a crucial role in the epithelial-mesenchymal transition, leading to lung cancer cells' enhanced motility.
Bajkowska K; Sumardika IW; Tomonobu N; Chen Y; Yamamoto KI; Kinoshita R; Murata H; Gede Yoni Komalasari NL; Jiang F; Yamauchi A; Winarsa Ruma IM; Kasano-Camones CI; Inoue Y; Sakaguchi M
Biochem Biophys Rep; 2020 Jul; 22():100768. PubMed ID: 32490214
[TBL] [Abstract][Full Text] [Related]
4. exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.
Kinoshita R; Sato H; Yamauchi A; Takahashi Y; Inoue Y; Sumardika IW; Chen Y; Tomonobu N; Araki K; Shien K; Tomida S; Torigoe H; Namba K; Kurihara E; Ogoshi Y; Murata H; Yamamoto KI; Futami J; Putranto EW; Ruma IMW; Yamamoto H; Soh J; Hibino T; Nishibori M; Kondo E; Toyooka S; Sakaguchi M
Int J Cancer; 2019 Jun; 144(12):3138-3145. PubMed ID: 30365872
[TBL] [Abstract][Full Text] [Related]
5. β-1,3-Galactosyl-
Sumardika IW; Youyi C; Kondo E; Inoue Y; Ruma IMW; Murata H; Kinoshita R; Yamamoto KI; Tomida S; Shien K; Sato H; Yamauchi A; Futami J; Putranto EW; Hibino T; Toyooka S; Nishibori M; Sakaguchi M
Oncol Res; 2018 Apr; 26(3):431-444. PubMed ID: 28923134
[TBL] [Abstract][Full Text] [Related]
6. S100A8/A9 activate key genes and pathways in colon tumor progression.
Ichikawa M; Williams R; Wang L; Vogl T; Srikrishna G
Mol Cancer Res; 2011 Feb; 9(2):133-48. PubMed ID: 21228116
[TBL] [Abstract][Full Text] [Related]
7. Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness.
Chen Y; Sumardika IW; Tomonobu N; Kinoshita R; Inoue Y; Iioka H; Mitsui Y; Saito K; Ruma IMW; Sato H; Yamauchi A; Murata H; Yamamoto KI; Tomida S; Shien K; Yamamoto H; Soh J; Futami J; Kubo M; Putranto EW; Murakami T; Liu M; Hibino T; Nishibori M; Kondo E; Toyooka S; Sakaguchi M
Neoplasia; 2019 Jul; 21(7):627-640. PubMed ID: 31100639
[TBL] [Abstract][Full Text] [Related]
8. MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.
Ruma IM; Putranto EW; Kondo E; Murata H; Watanabe M; Huang P; Kinoshita R; Futami J; Inoue Y; Yamauchi A; Sumardika IW; Youyi C; Yamamoto K; Nasu Y; Nishibori M; Hibino T; Sakaguchi M
Clin Exp Metastasis; 2016 Aug; 33(6):609-27. PubMed ID: 27151304
[TBL] [Abstract][Full Text] [Related]
9. exMCAM-Fc, an S100A8/A9-mediated-metastasis blocker, efficiently reduced the number of circulating tumor cells that appeared in the blood flow.
Tomonobu N; Kinoshita R; Sakaguchi M
Mol Biol Rep; 2020 Jun; 47(6):4879-4883. PubMed ID: 32383137
[TBL] [Abstract][Full Text] [Related]
10. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
[TBL] [Abstract][Full Text] [Related]
11. Impact of S100A8/A9 expression on prostate cancer progression in vitro and in vivo.
Grebhardt S; Müller-Decker K; Bestvater F; Hershfinkel M; Mayer D
J Cell Physiol; 2014 May; 229(5):661-71. PubMed ID: 24122301
[TBL] [Abstract][Full Text] [Related]
12. RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition.
Yin C; Li H; Zhang B; Liu Y; Lu G; Lu S; Sun L; Qi Y; Li X; Chen W
Breast Cancer Res Treat; 2013 Nov; 142(2):297-309. PubMed ID: 24177755
[TBL] [Abstract][Full Text] [Related]
13. Identification of an S100A8 Receptor Neuroplastin-β and its Heterodimer Formation with EMMPRIN.
Sakaguchi M; Yamamoto M; Miyai M; Maeda T; Hiruma J; Murata H; Kinoshita R; Winarsa Ruma IM; Putranto EW; Inoue Y; Morizane S; Huh NH; Tsuboi R; Hibino T
J Invest Dermatol; 2016 Nov; 136(11):2240-2250. PubMed ID: 27388991
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 4 promotes bladder cancer progression upon S100A8/A9 binding, which requires TIRAP-mediated TPL2 activation.
Herik Rodrigo AG; Tomonobu N; Yoneda H; Kinoshita R; Mitsui Y; Sadahira T; Terawaki SI; Gohara Y; Gede Yoni Komalasari NL; Jiang F; Murata H; Yamamoto KI; Futami J; Yamauchi A; Kuribayashi F; Inoue Y; Kondo E; Toyooka S; Nishibori M; Watanabe M; Nasu Y; Sakaguchi M
Biochem Biophys Res Commun; 2022 Dec; 634():83-91. PubMed ID: 36240653
[TBL] [Abstract][Full Text] [Related]
15. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2.
Ghavami S; Kerkhoff C; Chazin WJ; Kadkhoda K; Xiao W; Zuse A; Hashemi M; Eshraghi M; Schulze-Osthoff K; Klonisch T; Los M
Biochim Biophys Acta; 2008 Feb; 1783(2):297-311. PubMed ID: 18060880
[TBL] [Abstract][Full Text] [Related]
16. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells.
Hermani A; De Servi B; Medunjanin S; Tessier PA; Mayer D
Exp Cell Res; 2006 Jan; 312(2):184-97. PubMed ID: 16297907
[TBL] [Abstract][Full Text] [Related]
17. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis.
Ghavami S; Chitayat S; Hashemi M; Eshraghi M; Chazin WJ; Halayko AJ; Kerkhoff C
Eur J Pharmacol; 2009 Dec; 625(1-3):73-83. PubMed ID: 19835859
[TBL] [Abstract][Full Text] [Related]
18. S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-κB signaling.
Volz HC; Laohachewin D; Seidel C; Lasitschka F; Keilbach K; Wienbrandt AR; Andrassy J; Bierhaus A; Kaya Z; Katus HA; Andrassy M
Basic Res Cardiol; 2012 Mar; 107(2):250. PubMed ID: 22318783
[TBL] [Abstract][Full Text] [Related]
19. Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.
Kinoshita R; Sato H; Yamauchi A; Takahashi Y; Inoue Y; Sumardika IW; Chen Y; Tomonobu N; Araki K; Shien K; Tomida S; Torigoe H; Namba K; Kurihara E; Ogoshi Y; Murata H; Yamamoto KI; Futami J; Putranto EW; Ruma IMW; Yamamoto H; Soh J; Hibino T; Nishibori M; Kondo E; Toyooka S; Sakaguchi M
Int J Cancer; 2019 Jul; 145(2):569-575. PubMed ID: 30414170
[TBL] [Abstract][Full Text] [Related]
20. IL-17 stimulates neutrophils to release S100A8/A9 to promote lung epithelial cell apoptosis in Mycoplasma pneumoniae-induced pneumonia in children.
Bai S; Wang W; Ye L; Fang L; Dong T; Zhang R; Wang X; Gao H; Shen B; Ding S
Biomed Pharmacother; 2021 Nov; 143():112184. PubMed ID: 34562768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
